Pseudoprogression in a Patient with Metastatic Lung Adenocarcinoma Treated with Nivolumab

Pseudoprogresión en una paciente con adenocarcinoma pulmonar metastásico tratada con nivolumab

To the Editor,

Immunotherapy has been accepted in recent years as an effective treatment for selected patients with locally advanced and metastatic non-small cell lung cancer, although its use can also be associated with unusual side effects that can sometimes pose a diagnostic and therapeutic challenge. We report the case of a patient with metastatic lung adenocarcinoma who, after treatment with nivolumab, developed tumor pseudoprogression that was initially misinterpreted, leading to her being referred for palliative care.

This was a 55-year-old woman who presented with headache, nausea, and vomiting. Computed tomography (CT) and magnetic resonance imaging (MRI) of the head showed a brain lesion in the right temporal lobe measuring 2.5×2.5 cm, with significant edema and midline shift. Whole body CT revealed a solitary pulmonary nodule in the right apex, measuring 23 mm, consistent with primary neoplasm. PET-CT was performed, showing a lesion with intense uptake in the right upper lung (RUL), suggestive of malignancy, with no evidence of viable tumor tissue with affinity for 18F-FDG in any other site. The patient underwent surgery for the brain lesion, and the pathology study reported metastatic adenocarcinoma of possible pulmonary origin (positive CK7 and TTF1, and negative CK20, hormone receptors, melanocyte markers, and neuroendocrine markers). She subsequently received holocranial radiotherapy and then underwent surgery for her lung lesion with right upper lobectomy and mediastinal lymphadenectomy by video-assisted thoracic surgery (VATS). The pathology report was consistent with lung adenocarcinoma (final definitive staging was pT2aN0M1b due to involvement of the visceral pleura). The molecular study showed no mutations or molecular translocations (EGFR, KRAS, BRAF, ALK and ROS1-negative). The patient received 2 cycles of cisplatin+pemetrexed, and her first follow-up CT performed 8 weeks later revealed the appearance of right inguinal lymphadenopathy and tumor-like pelvic masses located theoretically in the right uterine appendage and in the left paracolic gutter, so second-line treatment with nivolumab began (3 mg/kg every 15 days). Imaging studies performed at 8 weeks showed progression of the abdominopelvic and brain lesions, and the patient's general condition had deteriorated (ECOG 3), so she was referred to the palliative care unit. One year later, she attended the clinic with improvement of her general condition (ECOG 1) and a CT performed for re-assessment revealed that the abdominopelvic lesions and the brain lesions seen on the head MRI had disappeared (Fig. 1). The patient is currently in complete radiological response after 41 months of follow-up.

In recent years, the therapeutic options for advanced non-small cell lung cancer have increased significantly. This new therapeutic arsenal benefits some patients, but has introduced some different forms of toxicity. In this respect, immunomodulatory drugs may lead to complications associated with the immune system, with other comorbidities or treatments, and even paradoxical responses. Pseudoprogression is a form of clinical response consisting of radiological worsening of the disease during treatment for an undetermined period of time, that subsequently resolves. First

![Fig. 1. (A) Axial CT images of abdomen (left) and pelvis (right) showing right inguinal lymphadenopathy, a mass in the right adnexal region, and another in the left paracolic gutter (arrows). (B) Axial CT images of abdomen (left) and pelvis (right) obtained 8 weeks later, showing a striking increase in tumor lesions (arrows). (C) Axial CT images of abdomen (left) and pelvis (right) obtained 12 months later, demonstrating the disappearance of tumor lesions.](image-url)

Please cite this article as: Cabañero A, Gorospe L, Olmedo ME, Mezquita L. Pseudoprogresión en una paciente con adenocarcinoma pulmonar metastásico tratada con nivolumab. Arch Bronconeumol. 2019;55:168-169.
Electromagnetic Navigation Placement of Intratumoral Gold Fiducials for Stereotactic Radiation Therapy in Lung Cancer

Colocación de fiduciales de oro intraneoplásia pulmonar mediante navegación electromagnética para tratamiento con radioterapia estereotáctica

To the Editor,

Remarkable advances have been made in the treatment of lung cancer in recent years with the use of drugs aimed at therapeutic targets that have helped improve the prognosis of patients with disseminated disease. However, resectable lung tumors are being identified in increasing numbers of patients who cannot undergo surgery due to functional impairment, advanced age, or severe limiting comorbidities. Stereotactic body radiation therapy (SBRT) is a potentially curative alternative in the subgroup of patients with stage I lung cancers who are not candidates for surgery.1-3 SBRT uses a combination of fixed, reproducible anatomical structures as a reference for the administration of higher doses of radiation per fraction to the target lesion. For successful treatment and minimization of potential side effects, it is essential that the lesion is precisely identified. This underlying premise has supported the decision to implant fiducials within the tumor, as an essential preliminary step before delivering SBRT.

We report 2 cases of stage I lung cancer, unsuitable for surgery, in whom, after a multidisciplinary assessment by the chest tumor commission of our hospital, it was agreed to proceed with the implantation of fiducials using electromagnetic navigation (EMN) for subsequent treatment with SBRT. Our 2 patients constitute the first reported use of this technique in Spain.

References


Alberto Cabañero, a,b Luis Gorospe, a María Eugenia Olmedo, c Laura Mezquita d

a Servicio de Cirugía Torácica, Hospital Universitario Ramón y Cajal, Madrid, Spain
b Servicio de Radiodiagnóstico, Hospital Universitario Ramón y Cajal, Madrid, Spain
c Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, Spain
d Department of Adult Medicine, Institut de Cancèrologie Gustave Roussy, Paris, France

corresponding author.
E-mail address: alberto.cabanero@salud.madrid.org (A. Cabañero).

1579-2129 © 2018 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.